These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35190596)

  • 1. Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria.
    Andoni T; Wiggins J; Robinson R; Charlton R; Sandberg M; Eeles R
    Sci Rep; 2022 Feb; 12(1):2507. PubMed ID: 35190596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
    Beitsch PD; Whitworth PW; Hughes K; Patel R; Rosen B; Compagnoni G; Baron P; Simmons R; Smith LA; Grady I; Kinney M; Coomer C; Barbosa K; Holmes DR; Brown E; Gold L; Clark P; Riley L; Lyons S; Ruiz A; Kahn S; MacDonald H; Curcio L; Hardwick MK; Yang S; Esplin ED; Nussbaum RL
    J Clin Oncol; 2019 Feb; 37(6):453-460. PubMed ID: 30526229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insurance coverage does not predict outcomes of genetic testing: The search for meaning in payer decisions for germline cancer tests.
    Amendola LM; Hart MR; Bennett RL; Horike-Pyne M; Dorschner M; Shirts B; Jarvik GP
    J Genet Couns; 2019 Dec; 28(6):1208-1213. PubMed ID: 31317629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
    Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
    Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients.
    Tsaousis GN; Papadopoulou E; Agiannitopoulos K; Pepe G; Tsoulos N; Boukovinas I; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Kapsimalis A; Xepapadakis G; Psyrri A; Banu E; Eniu DT; Blidaru A; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
    Cancer Genomics Proteomics; 2022; 19(1):60-78. PubMed ID: 34949660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer.
    Lincoln SE; Nussbaum RL; Kurian AW; Nielsen SM; Das K; Michalski S; Yang S; Ngo N; Blanco A; Esplin ED
    JAMA Netw Open; 2020 Oct; 3(10):e2019452. PubMed ID: 33026450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
    Chang J; Seng S; Yoo J; Equivel P; Lum SS
    Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline.
    Tung N; Ricker C; Messersmith H; Balmaña J; Domchek S; Stoffel EM; Almhanna K; Arun B; Chavarri-Guerra Y; Cohen SA; Cragun D; Crew KD; Hall MJ; Idos G; Lopez G; Pal T; Pirzadeh-Miller S; Pritchard C; Rana HQ; Swami U; Vidal GA
    J Clin Oncol; 2024 Jul; 42(21):2599-2615. PubMed ID: 38759122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline Genetic Features of Young Individuals With Colorectal Cancer.
    Stoffel EM; Koeppe E; Everett J; Ulintz P; Kiel M; Osborne J; Williams L; Hanson K; Gruber SB; Rozek LS
    Gastroenterology; 2018 Mar; 154(4):897-905.e1. PubMed ID: 29146522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cascade testing for hereditary cancer: comprehensive multigene panels identify unexpected actionable findings in relatives.
    Heald B; Pirzadeh-Miller S; Ellsworth RE; Nielsen SM; Russell EM; Beitsch P; Esplin ED; Nussbaum RL; Pineda-Alvarez DE; Kurian AW; Hampel H
    J Natl Cancer Inst; 2024 Feb; 116(2):334-337. PubMed ID: 37756683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer.
    Maxwell KN; Hart SN; Vijai J; Schrader KA; Slavin TP; Thomas T; Wubbenhorst B; Ravichandran V; Moore RM; Hu C; Guidugli L; Wenz B; Domchek SM; Robson ME; Szabo C; Neuhausen SL; Weitzel JN; Offit K; Couch FJ; Nathanson KL
    Am J Hum Genet; 2016 May; 98(5):801-817. PubMed ID: 27153395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing.
    Horton C; Hoang L; Zimmermann H; Young C; Grzybowski J; Durda K; Vuong H; Burks D; Cass A; LaDuca H; Richardson ME; Harrison S; Chao EC; Karam R
    JAMA Oncol; 2024 Feb; 10(2):212-219. PubMed ID: 37924330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing Guidelines.
    Neben CL; Zimmer AD; Stedden W; van den Akker J; O'Connor R; Chan RC; Chen E; Tan Z; Leon A; Ji J; Topper S; Zhou AY
    J Mol Diagn; 2019 Jul; 21(4):646-657. PubMed ID: 31201024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
    Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
    JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanded Gene Panel Use for Women With Breast Cancer: Identification and Intervention Beyond Breast Cancer Risk.
    O'Leary E; Iacoboni D; Holle J; Michalski ST; Esplin ED; Yang S; Ouyang K
    Ann Surg Oncol; 2017 Oct; 24(10):3060-3066. PubMed ID: 28766213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline Mutations for Novel Candidate Predisposition Genes in Sporadic Schwannomatosis.
    Min BJ; Kang YK; Chung YG; Seo ME; Chang KB; Joo MW
    Clin Orthop Relat Res; 2020 Nov; 478(11):2442-2450. PubMed ID: 32281771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
    JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
    Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D
    Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program.
    Hermel DJ; McKinnon WC; Wood ME; Greenblatt MS
    Fam Cancer; 2017 Jan; 16(1):159-166. PubMed ID: 27401692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Underdiagnosis of Hereditary Colorectal Cancers Among Medicare Patients: Genetic Testing Criteria for Lynch Syndrome Miss the Mark.
    Muller C; Nielsen SM; Hatchell KE; Yang S; Michalski ST; Hamlington B; Nussbaum RL; Esplin ED; Kupfer SS
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34585040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.